Wytyczne ESC dotyczace rozpoznawania i postȩpowania w ostrej zatorowości płucnej w 2014 roku

Kardiologia Polska

Volumn 72, Issue 11, 2014, Pages 997-1053

  Konstantinides, Stavros ^a,b   Torbicki, Adam ^c   Agnelli, Giancarlo ^d   Danchin, Nicolas ^d   Fitzmaurice, David ^d   Galiè, Nazzareno ^d   Gibbs, J Simon R ^d   Huisman, Menno ^d   Humbert, Marc ^d,e   Kucher, Nils ^d   Lang, Irene ^d   Lankeit, Mareike ^a   Lekakis, John ^b   Maack, Christoph ^a   Mayer, Eckhard ^a   Meneveau, Nicolas ^d   Perrier, Arnaud ^d   Pruszczyk, Peter ^c   Rasmussen, Lars H ^d   Schindler, Thomas H ^d   Svítil, Pavel ^d   Noordegraaf, Anton Vonk ^d   Zamorano, Jose Luis ^d   Zompatori, Maurizio ^d   more..

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c Europejskie Centrum Zdrowia   (Poland)

^d European Respiratory Society ^*  (Spain)

^e European Respiratory Society (ERS)   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

CARDIOLOGY; EUROPE; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PULMONARY EMBOLISM; STANDARDS;

ANTICOAGULANTS; CARDIOLOGY; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PULMONARY EMBOLISM; SOCIETIES, MEDICAL;

EID: 84987755509     PISSN: 00229032     EISSN: 18974279     Source Type: Journal    
DOI: 10.5603/KP.2014.0211     Document Type: Review

References (474)

1. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol, 2008; 28: 370-372.
2. Cohen AT, Agnelli G, Anderson FA et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost, 2007; 98: 756-764.
3. Klok FA, van Kralingen KW, van Dijk AP et al. Quality of life in long-term survivors of acute pulmonary embolism. Chest, 2010; 138: 1432-1440.
4. Bonderman D, Wilkens H, Wakounig S et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J, 2009; 33: 325-331.
5. Condliffe R, Kiely DG, Gibbs JS et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J, 2009; 33: 332-338.
6. Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost, 2009; 102: 688-693.
7. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest, 1995; 108: 978-981.
8. Heit JA III, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a populationbased case-control study. Arch Intern Med, 2000; 160: 809-815.
9. Anderson FA Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation, 2003; 107 (23 suppl. 1): I9-I16.
10. Biss TT, Brandao LR, Kahr WH, Chan AK, Williams S. Clinical features and outcome of pulmonary embolism in children Br J Haematol, 2008; 142: 808-818.
11. Andrew M, David M, Adams M et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood, 1994; 83: 1251-1257.
12. Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr, 2004; 145: 563-565.
13. van Ommen CH, Heijboer H, Buller HR et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr, 2001; 139: 676-681.
14. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood, 2014; 123: 1794-1801.
15. Rogers MA, Levine DA, Blumberg N et al. Triggers of hospitalization for venous thromboembolism. Circulation, 2012; 125: 2092-2099.
16. Ku GH, White RH, Chew HK et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood, 2009; 113: 3911-3917.
17. Chew HK, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med, 2006; 166: 458-464.
18. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 2005; 293: 715-722.
19. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancerassociated venous thrombosis. Blood, 2013; 122: 1712-1723.
20. Gussoni G, Frasson S, La Regina M et al. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res, 2013; 131: 24-30.
21. Blanco-Molina A, Rota LL, Di Micco P et al. Venous thromboembolism during pregnancy, postpartum or during contraceptive use. Thromb Haemost, 2010; 103: 306-311.
22. Blanco-Molina A, Trujillo-Santos J, Tirado R et al. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost, 2009; 101: 478-482.
23. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost, 2008; 6: 632-637.
24. Henriksson P, Westerlund E, Wallen H et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ, 2013; 346: e8632.
25. Sweetland S, Beral V, Balkwill A et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost, 2012; 10: 2277-2286.
26. Clayton TC, Gaskin M, Meade TW. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. Int J Epidemiol, 2011; 40: 819-827.
27. Smeeth L, Cook C, Thomas S et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet, 2006; 367: 1075-1079.
28. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 2008; 111: 4902-4907.
29. Dijk FN, Curtin J, Lord D, Fitzgerald DA. Pulmonary embolismin children. Paediatr Respir Rev, 2012; 13: 112-122.
30. Piazza G, Goldhaber SZ. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation, 2010; 121: 2146-2150.
31. Severinsen MT, Kristensen SR, Johnsen SP et al. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost, 2009; 7: 1297-1303.
32. Steffen LM, Cushman M, Peacock JM et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology. J Thromb Haemost, 2009; 7: 746-751.
33. Ageno W, Becattini C, Brighton T et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation, 2008; 117: 93-102.
34. Montecucco F, Mach F. Should we focus on "venous vulnerability" instead of "plaque vulnerability" in symptomatic atherosclerotic patients? Thromb Haemost, 2011; 106: 995-996.
35. Piazza G, Goldhaber SZ, Lessard DM et al. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost, 2011; 106: 1095-1102.
36. Gresele P, Momi S, Migliacci R. Endothelium, venousthromboembolism and ischaemic cardiovascular events. Thromb Haemost, 2010; 103: 56-61.
37. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost, 2005; 94: 362-365.
38. Enga KF, Braekkan SK, Hansen-Krone IJ et al. Cigarette smoking and the risk of venous thromboembolism: the Tromso Study. J Thromb Haemost, 2012; 10: 2068-2074.
39. Wattanakit K, Lutsey PL, Bell EJ et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost, 2012; 108: 508-515.
40. Sørensen HT, Horvath-Puho E, Lash TL et al. Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation, 2011; 124: 1435-1441.
41. Prandoni P, Pesavento R, Sorensen HT et al. Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey. Eur J Intern Med, 2009; 20: 470-473.
42. Sørensen HT, Horvath-Puho E, Pedersen L et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet, 2007; 370: 1773-1779.
43. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deepvein thrombosis. Lancet, 1969; 2: 230-232.
44. Dalen JE. Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis. Chest, 2002; 122: 1440-1456.
45. Kearon C. Natural history of venous thromboembolism. Circulation, 2003; 107 (23 suppl. 1): I22-I30.
46. Aujesky D, Obrosky DS, Stone RA et al. Aprediction rule to identify low-risk patients with pulmonary embolism. Arch Intern Med, 2006; 166: 169-175.
47. Laporte S, Mismetti P, Decousus H et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad Trombo Embolica venosa (RIETE) Registry. Circulation, 2008; 117: 1711-1716.
48. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet, 1999; 353: 1386-1389.
49. Miniati M, Monti S, Bottai M et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 2006; 85: 253-262.
50. Cosmi B, Nijkeuter M, Valentino M et al. Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. Intern Emerg Med, 2011; 6: 521-528.
51. Sanchez O, Helley D, Couchon S et al. Perfusion defects after pulmonary embolism: risk factors and clinical significance. J Thromb Haemost, 2010; 8: 1248-1255.
52. Becattini C, Agnelli G, Pesavento R et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest, 2006; 130: 172-175.
53. Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med, 2004; 350: 2257-2264.
54. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet, 2010; 376: 2032-2039.
55. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol, 2009; 29: 298-310.
56. Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol, 2012; 87 (suppl. 1): S63-S67.
57. Heit JA, Lahr BD, Petterson TM et al. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood, 2011; 118: 4992-4999.
58. Iorio A, Kearon C, Filippucci E et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med, 2010; 170: 1710-1716.
59. Douketis J, Tosetto A, Marcucci M et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ, 2011; 342: d813.
60. Lijfering WM, Veeger NJ, Middeldorp S et al. Alower risk of recurrent venous thrombosis inwomencompared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood, 2009; 114: 2031-2036.
61. Cosmi B, Legnani C, Tosetto A et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood, 2010; 115: 481-488.
62. Rodger MA, Kahn SR, Wells PS et al. Identifying unprovoked thromboembolism patients at low risk for recurrencewho can discontinue anticoagulant therapy. CMAJ, 2008; 179: 417-426.
63. Eichinger S, Minar E, Bialonczyk C et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA, 2003; 290: 1071-1074.
64. Coppens M, Reijnders JH, Middeldorp S et al. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost, 2008; 6: 1474-1477.
65. Kearon C, Julian JA, Kovacs MJ et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood, 2008; 112: 4432-4436.
66. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonaryembolism in patients without prior cardiopulmonary disease. Am J Cardiol, 1971; 28: 288-294.
67. Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res, 2000; 48: 23-33.
68. Delcroix M, Melot C, Lejeune P et al. Effects of vasodilators on gas exchange in acute canine embolic pulmonary hypertension. Anesthesiology, 1990; 72: 77-84.
69. Huet Y, Brun-Buisson C, Lemaire F et al. Cardiopulmonary effects of ketanserin infusion in human pulmonary embolism. Am Rev Respir Dis, 1987; 135: 114-117.
70. Lankhaar JW, Westerhof N, Faes TJ et al. Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol, 2006; 291: H1731-H1737.
71. Molloy WD, Lee KY, Girling L et al. Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis, 1984; 130: 870-874.
72. Marcus JT, Gan CT, Zwanenburg JJ et al. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. J Am Coll Cardiol, 2008; 51: 750-757.
73. Mauritz GJ, Marcus JT, Westerhof N et al. Prolonged right ventricular post-systolic isovolumic period in pulmonary arterial hypertension is not a reflection of diastolic dysfunction. Heart, 2011; 97: 473-478.
74. Begieneman MP, van de Goot FR, van der Bilt IA et al. Pulmonary embolism causes endomyocarditis in the human heart. Heart, 2008; 94: 450-456.
75. Hull RD, Raskob GE, Hirsh J et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med., 1986; 315: 1109-1114.
76. Lankeit M, Jimenez D, Kostrubiec M et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation, 2011; 124: 2716-2724.
77. Lankeit M, Kempf T, Dellas C et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med, 2008; 177: 1018-1025.
78. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J, 2003; 145: 821-825.
79. Burrowes KS, Clark AR, Tawhai MH. Blood flow redistribution and ventilationperfusion mismatch during embolic pulmonary arterial occlusion. Pulm Circ, 2011; 1: 365-376.
80. Konstantinides S, Geibel A, Kasper W et al. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism [see comments]. Circulation, 1998; 97: 1946-1951.
81. Miniati M, Prediletto R, Formichi B et al. Accuracy of clinical assessment in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med., 1999; 159: 864-871.
82. Pollack CV, Schreiber D, Goldhaber SZ et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol, 2011; 57: 700-706.
83. Wells PS, Ginsberg JS, Anderson DR et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med, 1998; 129: 997-1005.
84. Thames MD, Alpert JS, Dalen JE. Syncope in patients with pulmonary embolism. JAMA, 1977; 238: 2509-2511.
85. Stein PD, Henry JW. Clinical characteristics of patients with acute pulmonary embolism stratified according to their presenting syndromes. Chest, 1997; 112: 974-979.
86. White RH. The epidemiology of venous thromboembolism. Circulation, 2003; 107 (23 suppl. 1): I4-I8.
87. Rodger MA, Carrier M, Jones GN et al. Diagnostic value of arterial blood gas measurement in suspected pulmonary embolism. Am J Respir Crit Care Med, 2000; 162: 2105-2108.
88. Stein PD, Goldhaber SZ, Henry JW, Miller AC. Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. Chest, 1996; 109: 78-81.
89. Elliott CG, Goldhaber SZ, Visani L, DeRosa M. Chest radiographs in acute pulmonary embolism. Results from the International Cooperative Pulmonary Embolism Registry. Chest, 2000; 118: 33-38.
90. Geibel A, Zehender M, Kasper W et al. Prognostic value of the ECG on admission in patients with acute major pulmonary embolism. Eur Respir J, 2005; 25: 843-848.
91. Miniati M, Pistolesi M, Marini C et al. Value of perfusion lung scan in the diagnosis of pulmonary embolism: results of the Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis (PISA-PED). Am J Respir Crit Care Med, 1996; 154: 1387-1393.
92. Musset D, Parent F, Meyer G et al. Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet, 2002; 360: 1914-1920.
93. Le Gal G, Righini M, Roy PM et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med, 2006; 144: 165-171.
94. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolismdiagnosis (PIOPED). JAMA, 1990; 263: 2753-2759.
95. Wells PS, Anderson DR, Rodger M et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost, 2000; 83: 416-420.
96. Anderson DR, Kovacs MJ, Dennie C et al. Use of spiral computed tomography contrast angiography and ultrasonography to exclude the diagnosis of pulmonary embolism in the emergency department. J Emerg Med, 2005; 29: 399-404.
97. Kearon C, Ginsberg JS, Douketis J et al. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med, 2006; 144: 812-821.
98. Sohne M, Kamphuisen PW, van Mierlo PJ, Buller HR. Diagnostic strategy using a modified clinical decision rule and D-dimer test to rule out pulmonary embolism in elderly in- and outpatients. Thromb Haemost, 2005; 94: 206-210.
99. van Belle A, Buller HR, Huisman MV et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA, 2006; 295: 172-179.
100. Wells PS, Anderson DR, Rodger M et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med, 2001; 135: 98-107.
101. Rodger MA, Maser E, Stiell I et al. The interobserver reliability of pretest probability assessment in patients with suspected pulmonary embolism. Thromb Res, 2005; 116: 101-107.
102. Runyon MS, Webb WB, Jones AE, Kline JA. Comparison of the unstructured clinician estimate of pretest probability for pulmonary embolism to the Canadian score and the Charlotte rule: a prospective observational study. Acad Emerg Med, 2005; 12: 587-593.
103. Wolf SJ, McCubbin TR, Feldhaus KM et al. Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism. Ann Emerg Med, 2004; 44: 503-510.
104. Ceriani E, Combescure C, Le Gal G et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost, 2010; 8: 957-970.
105. Douma RA, Mos IC, Erkens PM et al. Performance of 4 clinical decision rules in the diagnosticmanagement of acute pulmonary embolism: a prospective cohort study. Ann Intern Med, 2011; 154: 709-718.
106. Lucassen W, Geersing GJ, Erkens PM et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. Ann Intern Med, 2011; 155: 448-460.
107. Gibson NS, Sohne M, Kruip MJ et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost, 2008; 99: 229-234.
108. Klok FA, Mos IC, Nijkeuter M et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med, 2008; 168: 2131-2136.
109. Douma RA, Gibson NS, Gerdes VE et al. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thromb Haemost, 2009; 101: 197-200.
110. Di Nisio M, Squizzato A, Rutjes AW et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost, 2007; 5: 296-304.
111. Stein PD, Hull RD, Patel KC et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med, 2004; 140: 589-602.
112. Perrier A, Roy PM, Aujesky D et al. Diagnosing pulmonary embolism in outpatients with clinical assessment, D-dimer measurement, venous ultrasound, and helical computed tomography: a multicenter management study. Am J Med, 2004; 116: 291-299.
113. Perrier A, Roy PM, Sanchez O et al. Multidetector-row computed tomography in suspected pulmonary embolism. N Engl J Med, 2005; 352: 1760-1768.
114. Perrier A, Desmarais S, Miron MJ et al. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet, 1999; 353: 190-195.
115. Kruip MJ, Slob MJ, Schijen JH et al. Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism: a prospective management study. Arch Intern Med, 2002; 162: 1631-1635.
116. Righini M, Le Gal G, Aujesky D et al. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet, 2008; 371: 1343-1352.
117. Carrier M, Righini M, Djurabi RK et al. VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies. Thromb Haemost, 2009; 101: 886-892.
118. Geersing GJ, Erkens PM, Lucassen WA et al. Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ, 2012; 345: e6564.
119. Righini M, Goehring C, Bounameaux H, Perrier A. Effects of age on the performance of common diagnostic tests for pulmonary embolism. Am J Med, 2000; 109: 357-361.
120. Douma RA, Le GG, Sohne M et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ, 2010; 340: c1475.
121. Penaloza A, Roy PM, Kline J et al. Performance of age-adjusted D-dimer cut-off to rule out pulmonary embolism. J Thromb Haemost, 2012; 10: 1291-1296.
122. Schouten HJ, Geersing GJ, Koek HL et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. BMJ, 2013; 346: f2492.
123. Righini M, Van Es J, den Exter PL et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA, 2014; 311: 1117-1124.
124. Di Nisio M, Sohne M, Kamphuisen PW, Buller HR. D-Dimer test in cancer patients with suspected acute pulmonary embolism. J Thromb Haemost, 2005; 3: 1239-1242.
125. Righini M, Le Gal G, De Lucia S et al. Clinical usefulness of D-dimer testing in cancer patients with suspected pulmonary embolism. Thromb Haemost, 2006; 95: 715-719.
126. Miron MJ, Perrier A, Bounameaux H et al. Contribution of noninvasive evaluation to the diagnosis of pulmonary embolism in hospitalized patients. Eur Respir J, 1999; 13: 1365-1370.
127. Chabloz P, Reber G, Boehlen F et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol, 2001; 115: 150-152.
128. Francalanci I, Comeglio P, Liotta AA et al. D-dimer concentrations during normal pregnancy, as measured by ELISA. Thromb Res, 1995; 78: 399-405.
129. Leclercq MG, Lutisan JG, van Marwijk Kooy M et al. Ruling out clinically suspected pulmonary embolism by assessment of clinical probability and D-dimer levels: a management study. Thromb Haemost, 2003; 89: 97-103.
130. Ten Wolde M, Hagen PJ, Macgillavry MR et al. Non-invasive diagnostic work-up of patients with clinically suspected pulmonary embolism; results of a management study. J Thromb Haemost, 2004; 2: 1110-1117.
131. Ghaye B, Szapiro D, Mastora I, Delannoy V et al. Peripheral pulmonary arteries: how far in the lung does multi-detector row spiral CT allow analysis? Radiology, 2001; 219: 629-636.
132. Patel S, Kazerooni EA, Cascade PN. Pulmonary embolism: optimization of small pulmonary artery visualization at multi-detector row CT. Radiology, 2003; 227: 455-460.
133. Remy-Jardin M, Remy J, Wattinne L, Giraud F. Central pulmonary thromboembolism: diagnosis with spiral volumetric CT with the single-breath-hold technique: comparison with pulmonary angiography. Radiology, 1992; 185: 381-387.
134. Stein PD, Fowler SE, Goodman LR et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med, 2006; 354: 2317-2327.
135. Anderson DR, Kahn SR, Rodger MA et al. Computed tomographic pulmonary angiography vs. ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA, 2007; 298: 2743-2753.
136. Carrier M, Righini M, Wells PS et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost, 2010; 8: 1716-1722.
137. Stein PD, Goodman LR, Hull RD, Dalen JE, Matta F. Diagnosis and management of isolated subsegmental pulmonary embolism: reviewand assessment of the options. Clin Appl Thromb Hemost, 2012; 18: 20-26.
138. Goodman LR, Stein PD, Matta F et al. CT venography and compression sonography are diagnostically equivalent: data from PIOPED II. Am J Roentgenol, 2007; 189: 1071-1076.
139. Brenner DJ, Hall EJ. Computed tomography: an increasing source of radiation exposure. N Engl J Med, 2007; 357: 2277-2284.
140. Farrell C, Jones M, Girvin F, Ritchie G, Murchison JT. Unsuspected pulmonary embolism identified using multidetector computed tomography in hospital outpatients. Clin Radiol, 2010; 65: 1-5.
141. Jia CF, Li YX, Yang ZQ et al. Prospective evaluation of unsuspected pulmonary embolism on coronary computed tomographic angiography. J Comput Assist Tomogr, 2012; 36: 187-190.
142. Palla A, Rossi G, Falaschi F et al. Is incidentally detected pulmonary embolism in cancer patients less severe? A case-control study. Cancer Invest, 2012; 30: 131-134.
143. Sahut D'Izarn M, Caumont Prim A, Planquette B et al. Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study. J Thromb Haemost, 2012; 10: 2032-2038.
144. Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141 (2 suppl.): e419S-e494S.
145. Alderson PO. Scintigraphic evaluation of pulmonary embolism. Eur J Nucl Med, 1987; 13 (suppl.): S6-S10.
146. Miller RF, O'Doherty MJ. Pulmonary nuclear medicine. Eur J Nucl Med, 1992; 19: 355-368.
147. Roach PJ, Schembri GP, Bailey DL. V/Q scanning using SPECTand SPECT/CT. J Nucl Med, 2013; 54: 1588-1596.
148. Schembri GP, Miller AE, Smart R. Radiation dosimetry and safety issues in the investigation of pulmonary embolism. Semin Nucl Med, 2010; 40: 442-454.
149. Reid JH, Coche EE, Inoue T et al. Is the lung scan alive and well? Facts and controversies in defining the role of lung scintigraphy for the diagnosis of pulmonary embolism in the era of MDCT. Eur J Nucl Med Mol Imaging, 2009; 36: 505-521.
150. Gottschalk A, Sostman HD, Coleman RE et al. Ventilation-perfusion scintigraphy in the PIOPED study. Part II. Evaluation of the scintigraphic criteria and interpretations. J Nucl Med, 1993; 34: 1119-1126.
151. Sostman HD, Coleman RE, DeLong DM et al. Evaluation of revised criteria for ventilation-perfusion scintigraphy in patients with suspected pulmonary embolism. Radiology, 1994; 193: 103-107.
152. Bajc M, Olsson B, Palmer J, Jonson B. Ventilation/perfusion SPECT for diagnostics of pulmonary embolism in clinical practice. J Intern Med, 2008; 264: 379-387.
153. Glaser JE, Chamarthy M, Haramati LB et al. Successful and safe implementation of a trinary interpretation and reporting strategy for V/Q lung scintigraphy. J Nucl Med, 2011; 52: 1508-1512.
154. Sostman HD, Stein PD, Gottschalk A et al. Acute pulmonary embolism: sensitivity and specificity of ventilation-perfusion scintigraphy in PIOPED II study. Radiology, 2008; 246: 941-946.
155. Stein PD, Terrin ML, Gottschalk A et al. Value of ventilation/perfusion scans vs. perfusion scans alone in acute pulmonary embolism. Am J Cardiol, 1992; 69: 1239-1241.
156. Miniati M, Monti S, Bauleo C et al. A diagnostic strategy for pulmonary embolism based on standardised pretest probability and perfusion lung scanning: a management study. Eur J Nucl Med Mol Imaging, 2003; 30: 1450-1456.
157. Roy PM, Colombet I, Durieux P et al. Systematic Review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. BMJ, 2005; 331: 259.
158. Collart JP, Roelants V, Vanpee D et al. Is a lung perfusion scan obtained by using single photon emission computed tomography able to improve the radionuclide diagnosis of pulmonary embolism? Nucl Med Commun, 2002; 23: 1107-1113.
159. Corbus HF, Seitz JP, Larson RK et al. Diagnostic usefulness of lung SPET in pulmonary thromboembolism: an outcome study. Nucl Med Commun, 1997; 18: 897-906.
160. Reinartz P, Wildberger JE, Schaefer W et al. Tomographic imaging in the diagnosis of pulmonary embolism: a comparison between V/Q lung scintigraphy in SPECT technique and multislice spiral CT. J Nucl Med, 2004; 45: 1501-1508.
161. Gutte H, Mortensen J, Jensen CV et al. Detection of pulmonary embolism with combined ventilation-perfusion SPECT and low-dose CT: head-to-head comparison with multidetector CT angiography. J Nucl Med, 2009; 50: 1987-1992.
162. Reinartz P, Kaiser HJ, Wildberger JE et al. SPECT imaging in the diagnosis of pulmonary embolism: automated detection of match and mismatch defects by means of image-processing techniques. J Nucl Med, 2006; 47: 968-973.
163. van Beek EJ, Reekers JA, Batchelor DA et al. Feasibility, safety and clinical utility of angiography in patients with suspected pulmonary embolism. Eur Radiol, 1996; 6: 415-419.
164. Diffin DC, Leyendecker JR, Johnson SP et al. Effect of anatomic distribution of pulmonary emboli on interobserver agreement in the interpretation of pulmonary angiography. Am J Roentgenol, 1998; 171: 1085-1089.
165. Stein PD, Henry JW, Gottschalk A. Reassessment of pulmonary angiography for the diagnosis of pulmonary embolism: relation of interpreteragreement to the order of the involved pulmonary arterial branch. Radiology, 1999; 210: 689-691.
166. Miller GA, Sutton GC, Kerr IH et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Heart J, 1971; 33: 616.
167. Stein PD, Athanasoulis C, Alavi A et al. Complications and validity of pulmonary angiography in acute pulmonary embolism. Circulation, 1992; 85: 462-468.
168. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysiscompared with heparyn for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation, 2004; 110: 744-749.
169. Engelberger RP, Kucher N. Catheter-based reperfusion treatment of pulmonary embolism. Circulation, 2011; 124: 2139-2144.
170. Revel MP, Sanchez O, Couchon S et al. Diagnostic accuracy of magnetic resonance imaging for an acute pulmonary embolism: results of the 'IRM-EP' study. J Thromb Haemost, 2012; 10: 743-750.
171. Stein PD, Chenevert TL, Fowler SE et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med, 2010; 152: 434-433.
172. Grifoni S, Olivotto I, Cecchini P et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation, 2000; 101: 2817-2822.
173. Torbicki A, Kurzyna M, Ciurzynski M et al. Proximal pulmonary emboli modify right ventricular ejection pattern. Eur Respir J, 1999; 13: 616-621.
174. Bova C, Greco F, Misuraca G et al. Diagnostic utility of echocardiography in patients with suspected pulmonary embolism. Am J Emerg Med, 2003; 21: 180-183.
175. Kurzyna M, Torbicki A, Pruszczyk P et al. Disturbed right ventricular ejection pattern as a new Doppler echocardiographic sign of acute pulmonary embolism. Am J Cardiol, 2002; 90: 507-511.
176. Casazza F, Bongarzoni A, Capozi A, Agostoni O. Regional right ventricular dysfunction in acute pulmonary embolism and right ventricular infarction. Eur J Echocardiogr, 2005; 6: 11-14.
177. Pruszczyk P, Goliszek S, Lichodziejewska B et al. Prognostic value of echocardiography in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol Cardiovasc Imaging, 2014; 7: 553-560.
178. Rudski LG, Lai WW, Afilalo J et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr, 2010; 23: 685-713.
179. Platz E, Hassanein AH, Shah A et al. Regional right ventricular strain pattern in patients with acute pulmonary embolism. Echocardiography, 2012; 29: 464-470.
180. Sugiura E, Dohi K, Onishi K et al. Reversible right ventricular regional non-uniformity quantified by speckle-tracking strain imaging in patients with acute pulmonary thromboembolism. J Am Soc Echocardiogr, 2009; 22: 1353-1359.
181. Hsiao SH, Chang SM, Lee CY et al. Usefulness of tissue Doppler parameters for identifying pulmonary embolism in patients with signs of pulmonary hypertension. Am J Cardiol, 2006; 98: 685-690.
182. Kucher N, Luder CM, Dornhofer T et al. Novel management strategy for patients with suspected pulmonary embolism. Eur Heart J, 2003; 24: 366-376.
183. Mansencal N, Attias D, Caille V et al. Computed tomography for the detection of free-floating thrombi in the right heart in acute pulmonary embolism. Eur Radiol, 2011; 21: 240-245.
184. Torbicki A, Galie N, Covezzoli A et al. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol, 2003; 41: 2245-2251.
185. Casazza F, Bongarzoni A, Centonze F, Morpurgo M. Prevalence and prognostic significance of right-sided cardiac mobile thrombi in acute massive pulmonary embolism. Am J Cardiol, 1997; 79: 1433-1435.
186. Mollazadeh R, Ostovan MA, Abdi Ardekani AR. Right cardiac thrombus in transit among patients with pulmonary thromboemboli. Clin Cardiol, 2009; 32: E27-E31.
187. Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest, 2002; 121: 806-814.
188. Krivec B, Voga G, Zuran I et al. Diagnosis and treatment of shock due to massive pulmonary embolism: approach with transesophageal echocardiography and intrapulmonary thrombolysis. Chest, 1997; 112: 1310-1316.
189. Pruszczyk P, Torbicki A, Kuch-Wocial A et al. Diagnostic value of transoesophageal echocardiography in suspected haemodynamically significant pulmonary embolism. Heart, 2001; 85: 628-634.
190. Pruszczyk P, Torbicki A, Pacho R et al. Noninvasive diagnosis of suspected severe pulmonary embolism: transesophageal echocardiography vs. spiral CT. Chest, 1997; 112: 722-728.
191. Hull RD, Hirsh J, Carter CJ et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med, 1983; 98: 891-899.
192. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med, 1998; 129: 1044-1049.
193. Perrier A, Bounameaux H. Ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med, 1998; 128: 243-245.
194. Le Gal G, Righini M, Sanchez O et al. Apositive compression ultrasonography of the lower limb veins is highly predictive of pulmonary embolism on computed tomography in suspected patients. Thromb Haemost, 2006; 95: 963-966.
195. Elias A, Colombier D, Victor G et al. Diagnostic performance of complete lower limb venous ultrasound in patients with clinically suspected acute pulmonary embolism. Thromb Haemost, 2004; 91: 187-195.
196. Righini M, Le GG, Aujesky D et al. Complete venous ultrasound in outpatients with suspected pulmonary embolism. J Thromb Haemost, 2009; 7: 406-412.
197. Kline JA, Webb WB, Jones AE, Hernandez-Nino J. Impact of a rapid rule-out protocol for pulmonary embolism on the rate of screening, missed cases, and pulmonary vascular imaging in an urban US emergency department. Ann Emerg Med, 2004; 44: 490-502.
198. Roy PM, Meyer G, Vielle B et al. Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. Ann Intern Med, 2006; 144: 157-164.
199. Ferrari E, Benhamou M, Berthier F, Baudouy M. Mobile thrombi of the right heart in pulmonary embolism: delayed disappearance after thrombolytic treatment. Chest, 2005; 127: 1051-1053.
200. Pierre-Justin G, Pierard LA. Management of mobile right heart thrombi: a prospective series. Int J Cardiol, 2005; 99: 381-388.
201. Vieillard-Baron A, Qanadli SD, Antakly Y et al. Transesophageal echocardiography for the diagnosis of pulmonary embolism with acute cor pulmonale: a comparison with radiological procedures. Intensive Care Med, 1998; 24: 429-433.
202. Righini M, Aujesky D, Roy PM et al. Clinical usefulness of D-dimer depending on clinical probability and cutoff value in outpatients with suspected pulmonary embolism. Arch Intern Med, 2004; 164: 2483-2487.
203. Perrier A, Miron MJ, Desmarais S et al. Using clinical evaluation and lung scan to rule out suspected pulmonary embolism: is it a valid option in patients with normal results of lower-limb venous compression ultrasonography? Arch Intern Med, 2000; 160: 512-516.
204. Stein PD, Sostman HD, Dalen JE et al. Controversies in diagnosis of pulmonary embolism. Clin Appl Thromb Hemost, 2011; 17: 140-149.
205. den Exter PL, Van Es J, Klok FA et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood, 2013; 122: 1144-1149.
206. Wiener RS, Schwartz LM, Woloshin S. Whena test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found. BMJ, 2013; 347: f3368.
207. Tsai J, Grosse SD, Grant AM et al. Trends in in-hospital deaths among hospitalizations with pulmonary embolism. Arch Intern Med, 2012; 172: 960-961.
208. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med, 2011; 171: 831-837.
209. Ayaram D, Bellolio MF, Murad MH et al. Triple rule-out computed tomographic angiography for chest pain: a diagnostic systematic review and meta-analysis. Acad Emerg Med, 2013; 20: 861-871.
210. Jimenez D, Aujesky D, Diaz G et al. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med, 2010; 181: 983-991.
211. Chan CM, Woods C, Shorr AF. The validation and reproducibility of the pulmonary embolism severity index. J Thromb Haemost, 2010; 8: 1509-1514.
212. Donze J, Le Gal G, Fine MJ et al. Prospective validation of the pulmonary embolism severity index. A clinical prognostic model for pulmonary embolism. Thromb Haemost, 2008; 100: 943-948.
213. Vanni S, Nazerian P, Pepe G et al. Comparison of two prognostic models for acute pulmonary embolism: clinical vs. right ventricular dysfunction-guided approach. J Thromb Haemost, 2011; 9: 1916-1923.
214. Aujesky D, Obrosky DS, Stone RA et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med, 2005; 172: 1041-1046.
215. Jiménez D, Yusen RD, Otero R et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest, 2007; 132: 24-30.
216. Wicki J, Perrier A, Perneger TV et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost, 2000; 84: 548-552.
217. Aujesky D, Roy PM, Verschuren F et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet, 2011; 378: 41-48.
218. Jimenez D, Aujesky D, Moores L et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med, 2010; 170: 1383-1389.
219. Righini M, Roy PM, Meyer G et al. The Simplified pulmonary embolism severity index (PESI): validation of a clinical prognostic model for pulmonary embolism. J Thromb Haemost, 2011; 9: 2115-2117.
220. Sam A, Sanchez D, Gomez V et al. The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism. Eur Respir J, 2011; 37: 762-766.
221. Lankeit M, Gomez V, Wagner C et al. A strategy combining imaging and laboratory biomarkers in comparison with a simplified clinical score for risk stratification of patients with acute pulmonary embolism. Chest, 2012; 141: 916-922.
222. Spirk D, Aujesky D, Husmann M et al. Cardiac troponin testing and the simplified Pulmonary Embolism Severity Index. The SWIss Venous Thromboembolism Registry (SWIVTER). Thromb Haemost, 2011; 106: 978-984.
223. Kreit JW. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest, 2004; 125: 1539-1545.
224. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med., 2005; 165: 1777-1781.
225. ten Wolde M, Sohne M, Quak E et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med, 2004; 164: 1685-1689.
226. Coutance G, Cauderlier E, Ehtisham J et al. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis. Crit Care, 2011; 15: R103.
227. Sanchez O, Trinquart L, Colombet I et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J, 2008; 29: 1569-1577.
228. Becattini C, Agnelli G, Vedovati MC et al. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J, 2011; 32: 1657-1663.
229. Trujillo-Santos J, den Exter PL, Gomez V et al. Computed tomography-assessed right ventricular dysfunction and risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and meta-analysis. J Thromb Haemost, 2013; 11: 1823-1832.
230. Becattini C, Agnelli G, Germini F, Vedovati MC. Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. Eur Respir J, 2014; 43: 1678-1690.
231. Henzler T, Roeger S, Meyer M et al. Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction. Eur Respir J, 2012; 39: 919-926.
232. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic Review and meta-analysis. Am J Respir Crit Care Med, 2008; 178: 425-430.
233. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation, 2003; 108: 2191-2194.
234. Lankeit M, Jimenez D, Kostrubiec M et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J, 2014; 43: 1669-1677.
235. Vuilleumier N, Le Gal G, Verschuren F et al. Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost, 2009; 7: 391-398.
236. Kostrubiec M, Pruszczyk P, Bochowicz A et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J, 2005; 26: 2166-2172.
237. Agterof MJ, Schutgens RE, Snijder RJ et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost, 2010; 8: 1235-1241.
238. Coma-Canella I, Gamallo C, Martinez Onsurbe P, Lopez-Sendon J. Acute right ventricular infarction secondary to massive pulmonary embolism. Eur Heart J, 1988; 9: 534-540.
239. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation, 2007; 116: 427-433.
240. Jimenez D, Uresandi F, Otero R et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest, 2009; 136: 974-982.
241. Lankeit M, Friesen D, Aschoff J et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J, 2010; 31: 1836-1844.
242. Boscheri A, Wunderlich C, Langer M et al. Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk. Am Heart J, 2010; 160: 294-300.
243. Puls M, Dellas C, Lankeit M et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J, 2007; 28: 224-229.
244. Dellas C, Puls M, Lankeit M et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol, 2010; 55: 2150-2157.
245. Lankeit M, Friesen D, Schafer K et al. A simple score for rapid risk assessment of non-high-risk pulmonary embolism. Clin Res Cardiol, 2013; 102: 73-80.
246. Dellas C, Tschepe M, Seeber V et al. A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism. Thromb Haemost, 2014; 111: 5.
247. Kostrubiec M, Łabyk A, Pedowska-Włoszek J et al. Assessment of renal dysfunction improves troponin-based short-term prognosis in patients with acute symptomatic pulmonary embolism. J Thromb Haemost, 2010; 8: 651-658.
248. Kostrubiec M, Łabyk A, Pedowska-Włloszek J et al. Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR indicate acute kidney injury and predict prognosis of patients with acute pulmonary embolism. Heart, 2012; 98: 1221-1228.
249. Becattini C, Lignani A, Masotti L et al. D-dimer for risk stratification in patients with acute pulmonary embolism. J Thromb Thrombolysis, 2012; 33: 48-57.
250. Lobo JL, Zorrilla V, Aizpuru F et al. D-dimer levels and 15-day outcome in acute pulmonaryembolism. Findings from the RIETE Registry. J Thromb Haemost, 2009; 7: 1795-1801.
251. Aujesky D, Roy PM, Guy M et al. Prognostic value of D-dimer in patients with pulmonary embolism. Thromb Haemost, 2006; 96: 478-482.
252. Konstantinides S, Geibel A, Heusel G et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med, 2002; 347: 1143-1150.
253. Meyer G, Vicaut E, Danays T et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med, 2014; 370: 1402-1411.
254. Jimenez D, Aujesky D, Moores L et al. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax, 2011; 66: 75-81.
255. Agterof MJ, Schutgens RE, Moumli N et al. A prognostic model for short term adverse events in normotensive patients with pulmonary embolism. Am J Hematol, 2011; 86: 646-649.
256. Becattini C, Casazza F, Forgione C et al. Acute pulmonary embolism: external validation of an integrated risk stratification model. Chest, 2013; 144: 1539-1545.
257. Sanchez O, Trinquart L, Caille V et al. Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study. Am J Respir Crit Care Med, 2010; 181: 168-173.
258. Jimenez D, Kopecna D, Tapson V et al.; on behalf of the Protect Investigators. Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med, 2014; 189: 718-726.
259. Bova C, Sanchez O, Prandoni P et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J, 2014; 44: 694-703.
260. Binder L, Pieske B, Olschewski M et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonaryembolism. Circulation, 2005; 112: 1573-1579.
261. The PEITHO Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J, 2012; 163: 33-38.
262. Sanchez O, Trinquart L, Planquette B et al. Echocardiography and pulmonary embolism severity index have independent prognostic roles in pulmonary embolism. Eur Respir J, 2013; 42: 681-688.
263. Ghignone M, Girling L, Prewitt RM. Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology, 1984; 60: 132-135.
264. Mercat A, Diehl JL, Meyer G et al. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med, 1999; 27: 540-544.
265. Manier G, Castaing Y. Influence of cardiac output on oxygen exchange in acute pulmonary embolism. Am Rev Respir Dis, 1992; 145:130-136.
266. Capellier G, Jacques T, Balvay P et al. Inhaled nitric oxide in patients with pulmonary embolism. Intensive Care Med, 1997; 23: 1089-1092.
267. Szold O, Khoury W, Biderman P et al. Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: a report of four patients and review of the literature. Lung, 2006; 184: 1-5.
268. Kerbaul F, Gariboldi V, Giorgi R et al. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med, 2007; 35: 1948-1954.
269. Kjaergaard B, Rasmussen BS, de Neergaard S et al. Extracorporeal cardiopulmonary support may be an efficient rescue of patients after massive pulmonary embolism. An experimental porcine study. Thromb Res, 2012; 129: e147-e151.
270. Delnoij TS, Accord RE, Weerwind PW, Donker DW. Atrial trans-septal thrombus in massive pulmonary embolismsalvaged by prolonged extracorporeal life suport after thromboembolectomy. A bridge to right-sided cardiovascular adaptation. Acute Card Care, 2012; 14: 138-140.
271. Leick J, Liebetrau C, Szardien S et al. Percutaneous circulatory support in a patient with cardiac arrest due to acute pulmonary embolism. Clin Res Cardiol, 2012; 101: 1017-1020.
272. Taniguchi S, Fukuda W, Fukuda I et al. Outcome of pulmonary embolectomy for acute pulmonary thromboembolism: analysis of 32 patients from a multicentre registry in Japan. Interact Cardiovasc Thorac Surg, 2012; 14: 64-67.
273. Cossette B, Pelletier ME, Carrier N et al. Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative. Ann Pharmacother, 2010; 44: 994-1002.
274. van Dongen CJ, van den Belt AG et al. Fixed dose subcutaneous low molecular weight heparins vs. adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev, 2004; 4: CD001100.
275. Stein PD, Hull RD, Matta F et al. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med, 2009; 122: 919-930.
276. Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood, 2005; 106: 3049-3054.
277. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weightbased heparin nomogram as a practice guideline. Arch Intern Med, 1996; 156: 1645-1649.
278. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin vs. a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.N Engl J Med, 2003; 349: 146-153.
279. Middeldorp S. How I treat pregnancy-related venous thromboembolism. Blood, 2011; 118: 5394-5400.
280. Samama MM, Poller L. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med, 1995; 15: 119-123.
281. Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med, 2003; 349: 1695-1702.
282. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med, 2007; 356: 2653-2655.
283. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141 (2 suppl.): e24S-e43S.
284. De Caterina R, Husted S, Wallentin L et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESCWorking Group on Thrombosis: Task Force on Anticoagulants in Heart Disease. Thromb Haemost, 2013; 110: 1087-1107.
285. British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet, 1992; 340: 873-876.
286. Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation, 2011; 124: 2554-2559.
287. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol, 2010; 55: 2804-2812.
288. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci, 2009; 30: 375-386.
289. Anderson JL, Horne BD, Stevens SM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation, 2012; 125: 1997-2005.
290. Verhoef TI, Ragia G, de Boer A et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med, 2013; 369: 2304-2312.
291. Kimmel SE, French B, Kasner SE et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med, 2013; 369: 2283-2293.
292. Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med, 2013; 369: 2294-2303.
293. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med, 2009; 361: 2342-2352.
294. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation, 2014; 129: 764-772.
295. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010; 363: 2499-2510.
296. Buller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med, 2012; 366: 1287-1297.
297. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 2013; 369: 799-808.
298. Buller HR, Decousus H, Grosso MA et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med, 2013; 369: 1406-1415.
299. van der Hulle T, Kooiman J, den Exter PL et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost, 2014; 12: 320-328.
300. Heidbuchel H, Verhamme P, Alings M et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J, 2013; 34: 2094-2106.
301. Dalla-Volta S, Palla A, Santolicandro A et al. PAIMS 2: alteplase combined with heparyn versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol, 1992; 20: 520-526.
302. Goldhaber SZ, Haire WD, Feldstein ML et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet, 1993; 341: 507-511.
303. Becattini C, Agnelli G, Salvi A et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res, 2010; 125: e82-e86.
304. Konstantinides S, Tiede N, Geibel A et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol, 1998; 82: 966-970.
305. Goldhaber SZ, Kessler CM, Heit J et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet, 1988; 2: 293-298.
306. Meneveau N, Schiele F, Vuillemenot A et al. Streptokinase vs. alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J, 1997; 18: 1141-1148.
307. Meneveau N, Schiele F, Metz D et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol, 1998; 31: 1057-1063.
308. Meyer G, Sors H, Charbonnier B et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol, 1992; 19: 239-245.
309. Tebbe U, Graf A, Kamke W et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J, 1999; 138 (1 Pt 1): 39-44.
310. Tebbe U, Bramlage P, Graf A et al. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost, 2009; 101: 557-562.
311. Kline JA, Nordenholz KE, Courtney DM et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost, 2014; 12: 459-468.
312. van De Werf F, Ardissino D, Betriu A et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2003; 24: 28-66.
313. Meneveau N, Seronde MF, Blonde MC et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest, 2006; 129: 1043-1050.
314. Daniels LB, Parker JA, Patel SR et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol, 1997; 80: 184-188.
315. Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med, 2012; 125: 465-470.
316. Kanter DS, Mikkola KM, Patel SR et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest, 1997; 111: 1241-1245.
317. Levine MN, Goldhaber SZ, Gore JM et al. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest, 1995; 108 (4 suppl.): 291S-301S.
318. Mikkola KM, Patel SR, Parker JA et al. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J, 1997; 134: 69-72.
319. Sharifi M, Bay C, Skrocki L et al. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol, 2013; 111: 273-277.
320. Wang C, Zhai Z, Yang Y et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest, 2010; 137: 254-262.
321. Chartier L, Bera J, Delomez M et al. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 3 8 consecutive patients. Circulation, 1999; 99: 2779-2783.
322. Kinney EL, Wright RJ. Efficacy of treatment of patients with echocardiographically detected right-sided heart thrombi: a meta-analysis. Am Heart J, 1989; 118: 569-573.
323. Myers PO, Bounameaux H, Panos A et al. Impending paradoxical embolism: systematic review of prognostic factors and treatment. Chest, 2010; 137: 164-170.
324. Mathew TC, Ramsaran EK, Aragam JR. Impending paradoxic embolismin acute pulmonary embolism: diagnosis by transesophageal echocardiography and treatment by emergent surgery. Am Heart J, 1995; 129: 826-827.
325. Kilic A, Shah AS, Conte JV, Yuh DD. Nationwide outcomes of surgical embolectomy for acute pulmonary embolism. J Thorac Cardiovasc Surg, 2013; 145: 373-377.
326. Malekan R, Saunders PC, Yu CJ et al. Peripheral extracorporeal membrane oxygenation: comprehensive therapy for highrisk massive pulmonary embolism. Ann Thorac Surg, 2012; 94: 104-108.
327. Takahashi H, Okada K, Matsumori M et al. Aggressive surgical treatment of acute pulmonary embolism with circulatory collapse. Ann Thorac Surg, 2012; 94: 785-791.
328. Leacche M, Unic D, Goldhaber SZ et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg, 2005; 129: 1018-1023.
329. Aymard T, Kadner A, Widmer A et al. Massive pulmonary embolism: surgical embolectomy versus thrombolytic therapy: should surgical indications be revisited? Eur J Cardiothorac Surg, 2013; 43: 90-94.
330. Fukuda I, Taniguchi S, Fukui K et al. Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients. Ann Thorac Surg, 2011; 91: 728-732.
331. Aklog L, Williams CS, Byrne JG, Goldhaber SZ. Acute pulmonary embolectomy: a contemporary approach. Circulation, 2002; 105: 1416-1419.
332. Greelish JP, Leacche M, Solenkova NS et al. Improved midterm outcomes for type A (central) pulmonary emboli treated surgically. J Thorac Cardiovasc Surg, 2011; 142: 1423-1429.
333. Vohra HA, Whistance RN, Mattam K et al. Early and late clinical outcomes of pulmonary embolectomy for acute massive pulmonary embolism. Ann Thorac Surg, 2010; 90: 1747-1752.
334. Kuo WT, Gould MK, Louie JD et al. Catheterdirected therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol, 2009; 20: 1431-1440.
335. Engelberger RP, Kucher N. Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review. Eur Heart J, 2014; 35: 758-764.
336. Kucher N, Boekstegers P, Muller OJ et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation, 2014; 129: 479-486.
337. Stein PD, Matta F, Keyes DC, Willyerd GL. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med, 2012; 125: 478-484.
338. Muriel A, Jimenez D, Aujesky D et al.; RIETE Investigators. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol, 2014; 63: 1675-1683.
339. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev, 2005; 19: 179-202.
340. Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med, 2011; 364: 861-869.
341. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 2005; 112: 416-422.
342. Failla PJ, Reed KD, Summer WR, Karam GH. Inferior vena caval filters: key considerations. Am J Med Sci, 2005; 330: 82-87.
343. Zhu X, Tam MD, Bartholomew J et al. Retrievability and device-related complications of the G2 filter: a retrospective study of 139 filter retrievals. J Vasc Interv Radiol, 2011; 22: 806-812.
344. Karmy-Jones R, Jurkovich GJ, Velmahos GC et al. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. J Trauma, 2007; 62: 17-24.
345. Pacouret G, Alison D, Pottier JM et al. Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep venous thrombosis. A prospective study. Arch Intern Med, 1997; 157: 305-308.
346. Squizzato A, Donadini MP, Galli L et al. Prognostic clinical prediction rules to identify a low-risk pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost, 2012; 10: 1276-1290.
347. Zondag W, Mos IC, Creemers-Schild D et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost, 2011; 9: 1500-1507.
348. Lankeit M, Konstantinides S. Is it time for home treatment of pulmonary embolism? Eur Respir J, 2012; 40: 742-749.
349. Otero R, Uresandi F, Jimenez D et al. Home treatment in pulmonary embolism. Thromb Res, 2010; 126: e1-e5.
350. Uresandi F, Otero R, Cayuela A et al. [A clinical prediction rule for identifying short-term risk of adverse events in patients with pulmonary thromboembolism]. Arch Bronconeumol, 2007; 43: 617-622.
351. Zondag W, Kooiman J, Klok FA et al. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J, 2013; 42: 134-144.
352. Brandjes DP, Heijboer H, Buller HR et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med, 1992; 327: 1485-1489.
353. Buller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med, 2004; 140: 867-873.
354. Hull RD, Raskob GE, Rosenbloom D et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med, 1990; 322: 1260-1264.
355. Decousus H, Leizorovicz A, Parent F et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group [see comments]. N Engl J Med, 1998; 338: 409-415.
356. Lee AY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol, 2005; 23: 2123-2129.
357. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol, 2004; 22: 1944-1948.
358. Agnelli G, Prandoni P, Becattini C et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med, 2003; 139: 19-25.
359. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost, 2002; 88: 407-414.
360. Schulman S, Granqvist S, Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med, 1997; 336: 393-398.
361. Schulman S. The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group. Wien Med Wochenschr, 1999; 149: 66-69.
362. Douketis JD, Gu CS, Schulman S et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med, 2007; 147: 766-774.
363. Schulman S, Rhedin AS, Lindmarker P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med, 1995; 332: 1661-1665.
364. Joung S, Robinson B. Venous thromboembolism in cancer patients in Christchurch, 1995-1999. N Z Med J, 2002; 115: 257-260.
365. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol, 2000; 18: 3078-3083.
366. Grifoni S, Vanni S, Magazzini S et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med, 2006; 166: 2151-2156.
367. Palareti G, Cosmi B, Legnani C et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med, 2006; 355: 1780-1789.
368. Becattini C, Agnelli G, Schenone A et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med, 2012; 366: 1959-1967.
369. Brighton TA, Eikelboom JW, Mann K et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med, 2012; 367: 1979-1987.
370. Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med, 2013; 368: 709-718.
371. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013; 368: 699-708.
372. Levine MN, Hirsh J, Gent M et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost, 1995; 74: 606-611.
373. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet, 1992; 340: 873-876.
374. Campbell IA, Bentley DP, Prescott RJ et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ, 2007; 334: 674.
375. Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism [published erratum appears in N Engl J Med, 1999 Jul 22; 341 (4): 298]. N Engl J Med, 1999; 340: 901-907.
376. Akl EA, Labedi N, Barba M et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev, 2011; 6: CD006650.
377. Akl EA, Vasireddi SR, Gunukula S et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev, 2011; 4: CD006649.
378. Pepke-Zaba J, Jansa P, Kim NH et al. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J, 2013; 41: 985-990.
379. Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J, 2009; 34: 1219-1263.
380. Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2013; 62 (25 suppl.): D34-D41.
381. Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J, 2013; 41: 462-468.
382. Lang IM, Simonneau G, Pepke-Zaba JW et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost, 2013; 110: 83-91.
383. Wong CL, Szydlo R, Gibbs S, Laffan M. Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis, 2010; 21: 201-206.
384. Bonderman D, Jakowitsch J, Redwan B et al. Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol, 2008; 28: 678-684.
385. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol, 2009; 53: 1211-1218.
386. Firth AL, Yao W, Ogawa A et al. Multipotent mesenchymal progenitor cells are present in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Cell Physiol, 2010; 298: C1217-C1225.
387. Yao W, Firth AL, Sacks RS et al. Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 2009; 296: L870-L878.
388. Morris TA, Marsh JJ, Chiles PG et al. High prevalence of dysfibrinogenemia among patients with chronić thromboembolic pulmonary hypertension. Blood, 2009; 114: 1929-1936.
389. Bonderman D, Skoro-Sajer N, Jakowitsch J et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation, 2007; 115: 2153-2158.
390. Delcroix M, Vonk Noordegraaf A, Fadel E et al. Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. Eur Respir J, 2013; 41: 224-232.
391. Madani MM, Auger WR, Pretorius V et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. Ann Thorac Surg, 2012; 94: 97-103.
392. Pepke-Zaba J, Delcroix M, Lang I et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation, 2011; 124: 1973-1981.
393. Berger RM, Beghetti M, Humpl T et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet, 2012; 379: 537-546.
394. Beghetti M, Berger RM, Schulze-Neick I et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J, 2013; 42: 689-700.
395. Tunariu N, Gibbs SJ, Win Z et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med, 2007; 48: 680-684.
396. Seferian A, Helal B, Jais X et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J, 2012; 40: 75-83.
397. Lang IM, Plank C, Sadushi-Kolici R et al. Imaging in pulmonary hypertension. JACC Cardiovasc Imaging, 2010; 3: 1287-1295.
398. Mayer E, Jenkins D, Lindner J et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg, 2011; 141: 702-710.
399. Cummings KW, Bhalla S. Multidetector computed tomographic pulmonary angiography: beyond acute pulmonary embolism. Radiol Clin North Am, 2010; 48: 51-65.
400. Sherrick AD, Swensen SJ, Hartman TE. Mosaic pattern of lung attenuation on CT scans: frequency among patients with pulmonary artery hypertension of different causes. Am J Roentgenol, 1997; 169: 79-82.
401. Ley S, Ley-Zaporozhan J, Pitton MB et al. Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronić thromboembolic pulmonary hypertension (CTEPH). Eur Radiol, 2012; 22: 607-616.
402. Shure D, Gregoratos G, Moser KM. Fiberoptic angioscopy: role in the diagnosis of chronic pulmonary arterial obstruction. Ann Intern Med, 1985; 103 (Pt 1): 844-850.
403. Jenkins DP, Madani M, Mayer E et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J, 2013; 41: 735-742.
404. Vuylsteke A, Sharples L, Charman G et al. Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet, 2011; 378: 1379-1387.
405. Mizoguchi H, Ogawa A, Munemasa M et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv, 2012; 5: 748-755.
406. Andreassen AK, Ragnarsson A, Gude E et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart, 2013; 99: 1415-1420.
407. Inami T, Kataoka M, Shimura N et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. J Am Coll Cardiol Cardiovasc Interv, 2013; 6: 725-736.
408. Kataoka M, Inami T, Hayashida K et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv, 2012; 5: 756-762.
409. Pepke-Zaba J, Jansa P, Kim NH et al. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J, 2013; 41: 985-990.
410. Jais X, D'Armini AM, Jansa P et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol, 2008; 52: 2127-2134.
411. Ghofrani HA, D'Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med, 2013; 369: 319-329.
412. Kim NH, Delcroix M, Jenkins DP et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol, 2013; 62 (25 suppl.): D92-D99.
413. Jamieson SW, Kapelanski DP, Sakakibara N et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg, 2003; 76: 1457-1462.
414. Rubin LJ, Hoeper MM, Klepetko W et al. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc, 2006; 3: 601-607.
415. Sullivan EA, Ford JB, Chambers G, Slaytor EK. Maternal mortality in Australia, 1973-1996. Aust N Z J Obstet Gynaecol, 2004; 44: 452-457.
416. Regitz-Zagrosek V, Blomstrom LC, Borghi C et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J, 2011; 32: 3147-3197.
417. O'Connor C, Moriarty J, Walsh J et al. The application of a clinical risk stratification score may reduce unnecessary investigations for pulmonary embolism in pregnancy. J Matern Fetal Neonatal Med, 2011; 24: 1461-1464.
418. Chan WS, Chunilal S, Lee A et al. A red blood cel agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med, 2007; 147: 165-170.
419. Chan WS, Lee A, Spencer FA et al. D-dimer testing in pregnant patients: towards determining the next 'level' in the diagnosis of deep vein thrombosis. J Thromb Haemost, 2010; 8: 1004-1011.
420. Ginsberg JS, Hirsh J, Rainbow AJ, Coates G. Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost, 1989; 61: 189-196.
421. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA, 2007; 298: 317-323.
422. Revel MP, Cohen S, Sanchez O et al. Pulmonary embolism during pregnancy: diagnosis with lung scintigraphy or CT angiography? Radiology, 2011; 258: 590-598.
423. Shahir K, Goodman LR, Tali A et al. Pulmonary embolism in pregnancy: CT pulmonary angiography versus perfusion scanning. Am J Roentgenol, 2010; 195: W214-W220.
424. Cahill AG, Stout MJ, Macones GA, Bhalla S. Diagnosing pulmonary embolism in pregnancy using computed-tomographic angiography or ventilation-perfusion. Obstet Gynecol, 2009; 114: 124-129.
425. Ridge CA, McDermott S, Freyne BJ et al. Pulmonary embolism in pregnancy: comparison of pulmonary CT angiography and lung scintigraphy. Am J Roentgenol, 2009; 193: 1223-1227.
426. Scarsbrook AF, Bradley KM, Gleeson FV. Perfusion scintigraphy: diagnostic utility in pregnant women with suspected pulmonary embolic disease. Eur Radiol, 2007; 17: 2554-2560.
427. Chan WS, Ray JG, Murray S et al. Suspected pulmonary embolism in pregnancy: clinical presentation, results of lung scanning, and subsequent maternal and pediatric outcomes. Arch Intern Med, 2002; 162: 1170-1175.
428. Balan KK, Critchley M, Vedavathy KK et al. The value of ventilation-perfusion imaging in pregnancy. Br J Radiol, 1997; 70: 338-340.
429. Bourjeily G, Khalil H, Raker C et al. Outcomes of negative multi-detector computed tomography with pulmonary angiography in pregnant women suspected of pulmonary embolism. Lung, 2012; 190: 105-111.
430. Bajc M, Neilly JB, Miniati M et al. EANM guidelines for ventilation/perfusion scintigraphy: Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur J Nucl Med Mol Imaging, 2009; 36: 1356-1370.
431. Chunilal SD, Bates SM. Venousthromboembolism in pregnancy: diagnosis, management and prevention. Thromb Haemost, 2009; 101: 428-438.
432. Romualdi E, Dentali F, Rancan E et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost, 2013; 11: 270-281.
433. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 2005; 106: 401-407.
434. Rodie VA, Thomson AJ, Stewart FM et al. Lowmolecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG, 2002; 109: 1020-1024.
435. Lepercq J, Conard J, Borel-Derlon A et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG, 2001; 108: 1134-1140.
436. Bates SM, Greer IA, Middeldorp S et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141 (2 suppl.): e691S-e736S.
437. Segal JB, Streiff MB, Hofmann LV et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med, 2007; 146: 211-222.
438. Leonhardt G, Gaul C, Nietsch HH et al. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis, 2006; 21: 271-276.
439. Cronin-Fenton DP, Søndergaard F, Pedersen LA et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer, 2010; 103: 947-953.
440. Palumbo A, Cavo M, Bringhen S et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myelomatreated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol, 2011; 29: 986-993.
441. Akl EA, Vasireddi SR, Gunukula S et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev, 2011; 4: CD006468.
442. Sweetland S, Green J, Liu B et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ, 2009; 339: b4583.
443. Douma RA, van Sluis GL, Kamphuisen PW et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost, 2010; 104: 831-836.
444. Dentali F, Ageno W, Becattini C et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res, 2010; 125: 518-522.
445. Engelke C, Manstein P, Rummeny EJ, Marten K. Suspected and incidental pulmonary embolism on multidetector-row CT: analysis of technical and morphological factors influencing the diagnosis in a cross-sectional cancer centre patient cohort. Clin Radiol, 2006; 61: 71-80.
446. Paddon AJ. Incidental pulmonary embolism detected by routine CT in patients with cancer. Cancer Imaging, 2005; 5: 25-26.
447. den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol, 2011; 29: 2405-2409.
448. Abdel-Razeq HN, Mansour AH, Ismael YM. Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome: a comprehensive cancer center experience. Vasc Health Risk Manag, 2011; 7: 153-158.
449. Sun JM, Kim TS, Lee J et al. Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. Lung Cancer, 2010; 69: 330-336.
450. Ruiz-Gimenez N, Suarez C, Gonzalez R et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost, 2008; 100: 26-31.
451. Nieto JA, Camara T, Gonzalez-Higueras E et al. RIETE I. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 789-796.
452. Levitan N, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore), 1999; 78: 285-291.
453. Louzada ML, Carrier M, Lazo-Langner A et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation, 2012; 126: 448-454.
454. Trujillo-Santos J, Nieto JA, Tiberio G et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost, 2008; 100: 435-439.
455. Carrier M, Le Gal G, Cho R et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost, 2009; 7: 760-765.
456. Barginear MF, Gralla RJ, Bradley TP et al. Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial. Support Care Cancer, 2012; 20: 2865-2872.
457. Trujillo-Santos J, Prandoni P, Rivron-Guillot K et al. Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost, 2008; 6: 251-255.
458. Sørensen HT, Svaerke C, Farkas DK et al. Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer, 2012; 48: 586-593.
459. Di Nisio M, Otten HM, Piccioli A et al. Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost, 2005; 3: 2391-2396.
460. van Doormaal FF, Terpstra W, Van Der Griend R et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost, 2011; 9: 79-84.
461. Farge D, Debourdeau P, Beckers M et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost, 2013; 11: 56-70.
462. Mandala M, Falanga A, Roila F, ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients:ESMO Clinical Practice Guidelines. Ann Oncol, 2011; 22 (suppl. 6): vi85-vi92.
463. Paddon AJ. Incidental pulmonary embolismdetected by routine CT in patients with cancer. Cancer Imaging, 2005; 5: 25-26.
464. Montagnana M, Cervellin G, Franchini M, Lippi G. Pathophysiology, clinics and diagnostics of non-thrombotic pulmonary embolism. J Thromb Thrombolysis, 2011; 31: 436-444.
465. Bach AG, Restrepo CS, Abbas J et al. Imaging of nonthrombotic pulmonary embolism: biological materials, nonbiological materials, and foreign bodies. Eur J Radiol, 2013; 82: e120-e141.
466. Sakuma M, Sugimura K, Nakamura M et al. Unusual pulmonary embolism: septic pulmonary embolism and amniotic fluid embolism. Circ J, 2007; 71: 772-775.
467. Wolf F, Schernthaner RE, Dirisamer A et al. Endovascular management of lost or misplaced intravascular objects: experiences of 12 years. Cardiovasc Intervent Radiol, 2008; 31: 563-568.
468. Parisi DM, Koval K, Egol K. Fat embolism syndrome. Am J Orthop (Belle Mead NJ), 2002; 31: 507-512.
469. Jorens PG, Van ME, Snoeckx A, Parizel PM. Nonthrombotic pulmonary embolism. Eur Respir J, 2009; 34: 452-474.
470. Lin CC, Liu PH, Kao SJ, Chen HI. Effects of phorbol myristate acetate and sivelestat on the lung injury caused by fat embolism in isolated lungs. J Biomed Sci, 2012; 19: 3.
471. Orebaugh SL. Venous air embolism: clinical and experimental considerations. Crit Care Med, 1992; 20: 1169-1177.
472. Muth CM, Shank ES. Gas embolism. N Engl J Med, 2000; 342: 476-482.
473. Knight M, Berg C, Brocklehurst P et al. Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth, 2012; 12: 7.
474. Roberts KE, Hamele-Bena D, Saqi A et al. Pulmonary tumor embolism: a review of the literature. Am J Med, 2003; 115: 228-232.